Eicosanoids and asthma: an update.
There have been significant advances in our understanding of the role of eicosanoids as mediators in inflammation since their discovery over 50 years ago. Our more recent understanding of asthma as an inflammatory disease has led to the appreciation of eicosanoids potentially being pivotal mediators in promoting some of the changes in asthma. Of particular importance are the cysteinyl LTs in producing bronchospasm and bronchial hyperresponsivenss, and PGE2 in modulating the bronchospastic and inflammatory response. Evidence from clinical studies suggests that other eicosanoids may also contribute, but their importance is secondary and their relative contributions vary between individuals. The development of new drugs based on our partial understanding of the role that eicosanoid mediators may play in asthma promises new approaches to the treatment of this common chronic inflammatory condition.
Thien
F C
FC
Department of Respiratory Medicine, Alfred Hospital, Prahran, Vic, Australia.
Walters
E H
EH
D001249:Asthma / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D015777:Eicosanoids / Q000737:chemistry / Q000502:physiology; D011464:Epoprostenol / Q000502:physiology; D006801:Humans; D020024:Leukotriene Antagonists; D007975:Leukotriene B4 / Q000502:physiology; D015289:Leukotrienes / Q000737:chemistry / Q000502:physiology; D016859:Lipoxygenase Inhibitors; D011453:Prostaglandins / Q000502:physiology; D013931:Thromboxanes / Q000502:physiology
D015777:Eicosanoids; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D011453:Prostaglandins; D013931:Thromboxanes; D007975:Leukotriene B4; D011464:Epoprostenol